Sign up
Pharma Capital
Why invest in PAR?

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions

Paul Rennie talked timeline to clinical trial results with investors.
Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
BigPicture
Paul Rennie, chief executive officer, Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, joined Proactive's CEO Sessions in Melbourne on Tuesday 16th May and Sydney on Wednesday 17th May.

Paradigm has results from its Phase 2 hay fever trial pending in six weeks.

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future PAR Company articles
View full PAR profile

Paradigm Biopharmaceuticals Ltd Timeline

View All

Related Articles

generic pill and bottle shot to denote Alliance's products
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.